Patents Examined by Tracy Vivlemore
  • Herbicidal pyrimidine compounds
    Patent number: 11178871
    Abstract: The present invention relates to the use of pyrimidine compounds of formula (I), or their agriculturally acceptable salts or derivatives as herbicides, wherein the variables are defined according to the description, specific pyrimidine compounds of formula (I), compositions comprising them and their use as herbicides, i.e. for controlling harmful plants, and also a method for controlling unwanted vegetation which comprises allowing a herbicidal effective amount of at least one pyrimidine compounds of the formula (I) to act on plants, their seed and/or their habitat.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: November 23, 2021
    Assignee: BASF SE
    Inventors: Florian Vogt, Matthias Witschel, Tobias Seiser, Veronica Lopez Carrillo, Thomas Seitz, Gerd Kraemer, Klaus Kreuz, Trevor William Newton, Klaus Reinhard, Doreen Schachtschabel
  • Morpholino modified oligomeric compounds
    Patent number: 11180756
    Abstract: The present invention provides morpholino modified oligomeric compounds having at least one monomer subunit having Formula III, compounds having Formula I useful for making certain of the morpholino modified oligomeric compounds and methods of using the oligomeric compounds. In certain embodiments, the oligomeric compounds provided herein provide for an improved toxicity profile. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount of activity or expression of the target nucleic acid in a cell.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: November 23, 2021
    Assignee: Ionis Pharmaceuticals
    Inventors: Michael Oestergaard, Punit P. Seth
  • Compositions and methods for inhibition of the JAK pathway
    Patent number: 11174251
    Abstract: Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful. Also disclosed are methods of making the compounds.
    Type: Grant
    Filed: October 17, 2019
    Date of Patent: November 16, 2021
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Hui Li, Thilo J. Heckrodt, Yan Chen, Darren John McMurtrie, Vanessa Taylor, Rajinder Singh, Pingyu Ding, Rose Yen
  • Products and compositions
    Patent number: 11174483
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with the TMPRSS6 gene expression or inhibits its expression and therapeutic uses such as for the treatment of hemochromatosis, porphyria and blood disorders such as ?-thalassemias, sickle cell disease and transfusional iron overload or myelodysplastic syndrome.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: November 16, 2021
    Assignee: Silence Therapeutics GmbH
    Inventors: Sibylle Dames, Ute Schaeper, Judith Hauptmann, Christian Frauendorf, Lucas Bethge, Adrien Weingärtner
  • Stimulators and/or activators of soluble guanylate cyclase (sGC) in combination with an inhibitor of neutral endopeptidase (NEP inhibitor) and/or an angiotensin AII antagonist and the use thereof
    Patent number: 11166932
    Abstract: The present invention relates to stimulators and activators of soluble guanylate cyclase in combination with an inhibitor of neutral endopeptidase and/or angiotensin AII antagonists and the use thereof for the treatment and/or prophylaxis of cardiovascular disorders, for example heart failure with preserved ejection fraction or heart failure with reduced ejection fraction, renal disorders, for example chronic kidney failure, urological disorders, lung disorders, disorders of the central nervous system, for regulation of cerebral perfusion, for example in the event of vascular cerebral states of dementia, for the treatment and/or prophylaxis of fibrotic disorders and other disease symptoms (e.g. end organ damage affecting the brain, kidney or heart).
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: November 9, 2021
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Tobias Marquardt, Markus Follmann, Johannes-Peter Stasch
  • Methods for treatment of polycystic kidney disease
    Patent number: 11168325
    Abstract: Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: November 9, 2021
    Assignees: Regulus Therapeutics Inc., Board of Regents of The University of Texas System
    Inventors: John R. Androsavich, B. Nelson Chau, Vishal D. Patel
  • Time-resolved fluorescent immunochromatographic test strip for detecting vancomycin as well as preparation method and application thereof
    Patent number: 11162959
    Abstract: Some embodiments of the disclosure provide a time-resolved fluorescent immunochromato-graphic test strip for detecting vancomycin as well as a preparation method and application thereof. In some embodiments, the test strip includes a bottom plate and a sample absorption pad. A fluorescent microsphere pad, a nitrocellulose membrane coated with a vancomycin-carrier protein conjugate, and an absorbent pad are sequentially overlapped and pasted on the bottom plate. The fluorescent microsphere pad is sprayed with a fluorescent microsphere-labeled vancomycin monoclonal antibody, and the vancomycin monoclonal antibody is prepared by using a vancomycin-bovine serum albumin conjugate as an immunogen.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: November 2, 2021
    Assignee: Beijing Diagreat Biotechnologies Co., LTD.
    Inventors: Xiuli Xu, Yanxin Wang, Yuanrong Chang, Jianping Zhou
  • Methods for generating structure-switching aptamers and uses thereof
    Patent number: 11162960
    Abstract: The subject invention provides methods, assays, and products for detecting small-molecule targets in a complex sample in both clinical and field settings. The subject invention provides aptamer-based sensors and methods of use thereof. The subject invention provides exonuclease-based methods for generating structure-switching aptamers from fully folded or pre-folded aptamers and developing aptamer-based sensors for small-molecule detection. The method for detecting one or more small-molecule targets in a sample comprises contacting the sample with one or more aptamer-based sensor selective for each of the small-molecule targets, and detecting the small-molecule target in the sample.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: November 2, 2021
    Assignee: THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES
    Inventors: Yi Xiao, Haixiang Yu, Juan Canoura, Yingzhu Liu
  • Modulators of proteolysis and associated methods of use
    Patent number: 11161841
    Abstract: The present disclosure relates to bifunctional compounds, which find utility as modulators of Kirsten rat sarcoma protein (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation, accumulation, and/or overactivation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
    Type: Grant
    Filed: April 4, 2019
    Date of Patent: November 2, 2021
    Assignee: ARVINAS OPERATIONS, INC.
    Inventors: Andrew P. Crew, Keith R. Hornberger, Jing Wang, Hanqing Dong
  • Method for suppressing nonspecific signals from contaminants in an immunoassay using surface plasmon-field enhanced fluorescence spectroscopy (SPFS)
    Patent number: 11162940
    Abstract: Provided is at least one method of suppressing, in an immunoassay using surface plasmon-field enhanced fluorescence spectroscopy (SPFS), nonspecific signals generated by nonspecific adsorption of contaminants contained in a sample to an SPFS sensor section (e.g., a primary antibody, a solid-phase layer and a metal thin film). At least one method relates to a method of suppressing nonspecific signals originating from contaminants in an immunoassay using surface plasmon-field enhanced fluorescence spectroscopy (SPFS) (including cases where a receptor for a compound to be measured is used in place of a primary antibody), the method comprising performing at least one pretreatment.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: November 2, 2021
    Assignee: KONICA MINOLTA, INC.
    Inventors: Tomonori Kaneko, Takeshi Isoda
  • Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
    Patent number: 11162103
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the apolipoprotein C3 gene (APOC3). The invention also relates to methods of using such RNAi agents to inhibit expression of an APOC3 gene and to methods of preventing and treating an APOC3-associated disorder, e.g., hypertriglyceridemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, polycystic ovary syndrome, kidney disease, obesity, type 2 diabetes mellitus (insulin resistance), hypertension, artherosclerosis and pancreatitis.
    Type: Grant
    Filed: February 22, 2021
    Date of Patent: November 2, 2021
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Frederic Tremblay, Lucas D. BonDurant, James D. McIninch, Adam Castoreno, Mark K. Schlegel, Charalambos Kaittanis
  • Rutaecarpine analogs and applications thereof
    Patent number: 11155552
    Abstract: The present invention provides RUT analogs with various biological activities. In particular, the biological activities comprise anti-inflammatory activity, vasodilator effects, migration/invasion-suppressive activities, ability against damage due to remodeling between the epithelium and endothelium, collagen deposition and cardiac fibrosis suppress, Snail protein inhibitory effect, etc., which may improve cardiac, vasodilation, and lung functions. The RUT analogs disclosed herein also exhibit a lower cytotoxicity comparing to RUT.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: October 26, 2021
    Assignees: TAIPEI MEDICAL UNIVERSITY, NATIONAL TAIPEI UNIVERSITY OF TECHNOLOGY
    Inventors: Chun-Mao Lin, Chi-Ming Lee, Chi Wang, Sheng-Tung Huang, Jiun-An Gu, Tin-An Rau
  • Amide derivatives as Nav1.7 and Nav1.8 blockers
    Patent number: 11154544
    Abstract: The present invention relates to amide derivatives which have blocking activities of voltage gated sodium channels as the Nav1.7 and Nav1.8 channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: October 26, 2021
    Assignee: RaQualia Pharma Inc.
    Inventors: Tatsuya Yamagishi, Mikio Morita, Yuji Shishido, Ryuichi Yamaguchi, Norikazu Gaja
  • Method for the site-specific covalent cross-linking of antibodies to surfaces
    Patent number: 11156608
    Abstract: This invention relates to conjugate antibody, drug and nanoparticle compositions and methods of generating the same. This invention further relates to methods of using same for imaging, diagnosing or treating a disease.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: October 26, 2021
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Andrew Tsourkas, James Z. Hui
  • Multilayer nanowire complex and method of preparing the same
    Patent number: 11156604
    Abstract: A method of preparing an immunological substance detection nanowire complex includes preparing a multilayer nanowire in which a first metal and a second metal are alternately stacked, attaching a polymer, having a carboxyl group and an amine group at both ends of the polymer, to the second metal, attaching a first antibody, treated with a thiol's group, to the first metal of the multilayer nanowire, and attaching a second antibody to the second metal through the carboxyl group of the polymer. The second antibody includes a phosphor.
    Type: Grant
    Filed: April 25, 2019
    Date of Patent: October 26, 2021
    Assignees: Korea University Research and Business Foundation, SNU R&DB Foundation
    Inventors: Young Keun Kim, Yoo Sang Jeon, Da-yeon Nam, Yu Jin Kim, Hang-Rae Kim, Hyun Mu Shin
  • Compounds for the treatment of neuromuscular disorders
    Patent number: 11147788
    Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: October 19, 2021
    Assignee: NMD PHARMA A/S
    Inventors: Lars J. S. Knutsen, Thomas Holm Pedersen, Martin Broch-Lipps, Claus Elsborg Olesen, Marc Labelle, Ole Baekgaard Nielsen
  • Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof
    Patent number: 11149276
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the Patatin-Like Phospholipase Domain Containing 3 (PNPLA3) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a PNPLA3 gene and to methods of preventing and treating an PNPLA3-associated disorder, e.g., Nonalcoholic Fatty Liver Disease (NAFLD).
    Type: Grant
    Filed: February 23, 2021
    Date of Patent: October 19, 2021
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Frederic Tremblay, James D. McIninch, Adam Castoreno, Mark K. Schlegel, Charalambos Kaittanis
  • Modified compounds and uses thereof
    Patent number: 11149264
    Abstract: The present disclosure provides oligomeric compound comprising a modified oligonucleotide having a central region comprising one or more modifications. In certain embodiments, the present disclosure provides oligomeric compounds having an improved therapeutic index or an increased maximum tolerated dose.
    Type: Grant
    Filed: February 10, 2021
    Date of Patent: October 19, 2021
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Punit P. Seth, Michael Oestergaard, Michael T. Migawa, Xue-hai Liang, Wen Shen, Stanley T. Crooke, Eric E. Swayze
  • Crystalline form of tegavivint, method of preparation, and use thereof
    Patent number: 11136307
    Abstract: The present invention relates to crystalline forms of (9E,10E)-2,7-bis((3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime, pharmaceutical compositions comprising the crystalline form, processes for preparing the crystalline form and methods of use therefore.
    Type: Grant
    Filed: September 29, 2020
    Date of Patent: October 5, 2021
    Assignee: ITERION THERAPEUTICS, INC.
    Inventors: Drazen Ostovic, Gowri Sukumar
  • Method for estimating Gleason score of prostate cancer, method for estimating pathological stage, and method for acquiring supplementary information, all on the basis of specific PSA content in specimen
    Patent number: 11137403
    Abstract: The present invention provides methods that are for acquiring various types of supplementary information used for diagnosis or treatment of prostate cancer, and that can be implemented in a less-invasive manner at a low cost. Provided are, by measuring the content of prostate specific antigen (PSA) having a ?-N-acetylgalactosamine residue at a non-reducing terminal of a sugar chain in a specimen, and comparing the measured value with a threshold value, (1) a method for estimating whether a Gleason score (primary pattern and secondary pattern) is not less than or less than a prescribed value, (2) a method for estimating whether the pathological stage (pT) is not less than or less than a prescribed value, and (3) a method for acquiring information for assessment indicating diagnosis or treatment should be actively conducted because a GS at gross total removal is expected to be higher than a GS at biopsy.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: October 5, 2021
    Assignees: Konica Minolta, Inc., HIROSAKI UNIVERSITY
    Inventors: Tomonori Kaneko, Takatoshi Kaya, Chikara Ohyama, Tohru Yoneyama, Yuki Tobisawa